BERWYN, Pa., Sept. 10, 2021 /PRNewswire/ -- Annovis Bio,
Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a
clinical-stage drug platform company addressing Alzheimer's disease
(AD), Parkinson's disease (PD) and other neurodegenerative
diseases, today announced CEO Maria L.
Maccecchini will present at the H.C. Wainwright
23rd Annual Global Investment Conference being held
virtually from September 13 – 15,
The presentation will be available on demand to conference
attendees. To register for the conference, visit:
About Annovis Bio, Inc.
Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc. (Annovis) is a
clinical-stage, drug platform company addressing neurodegeneration,
such as Alzheimer's disease (AD), Parkinson's disease (PD) and
Alzheimer's in Down Syndrome (AD-DS). We believe that we are the
only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and, thereby, improves the
information highway of the nerve cell, known as axonal transport.
When this information flow is impaired, the nerve cell gets sick
and dies. We have two ongoing Phase 2 studies: one in AD patients
and one in both AD and PD patients. In the AD/ PD study our drug
improves memory loss and dementia associated with AD, as well as
body and brain function in PD.
For more information on Annovis Bio, please visit the company's
Statements in this press release contain "forward-looking
statements" that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as "anticipate,"
"expect," "believe," "will," "may," "should," "estimate,"
"project," "outlook," "forecast" or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness, and anticipated results of ANVS401 clinical trials.
Forward-looking statements are based on Annovis Bio, Inc.'s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in the Annual Report on Form 10-K for the year ended
December 31, 2020 filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Annovis Bio, Inc. undertakes no duty to update such information
except as required under applicable law.
Media and Investor Relations Contact:
View original content to download
SOURCE Annovis Bio